NCT00602667 · OUTCOME
Growth Hormone Secretion
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- ng/mL
- Interval / dispersion
- Standard Deviation
- Time frame
- End of induction therapy (approximately 16 weeks from start of treatment), end of therapy (approximately 48 weeks from start of treatment), and 6, 12, 24, 36, 48, and 60 months off therapy
What was measured
Growth hormone secretion was measured in consenting intermediate risk patients at the end of induction therapy, the end of all therapy, and at 6, 12, 24, 36, 48, and 60 months off therapy. Mean growth hormone secretion values are reported by assessment time point. Please note the small numbers of participants with available data.
Analysis population: Growth hormone secretion was measured in consenting intermediate risk patients. No Intermediate Risk patients had data available at 12, 36, 48, and 60 months off therapy.
Groups in this outcome
Low-Risk Group
Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
Intermediate-Risk Group
Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
High-Risk Group
Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 20 |
|---|
| High-Risk Group | 0 |
|---|
Reported measurements
End of induction
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 10 |
|---|
| High-Risk Group | 0 |
|---|
Values in ng/mL · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Intermediate-Risk Group | 15.3 | 9.7 | Not reported | Not reported | Not reported |
|---|
End of therapy
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 8 |
|---|
| High-Risk Group | 0 |
|---|
Values in ng/mL · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Intermediate-Risk Group | 13.4 | 6.2 | Not reported | Not reported | Not reported |
|---|
6-months off therapy
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 2 |
|---|
| High-Risk Group | 0 |
|---|
Values in ng/mL · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Intermediate-Risk Group | 7.3 | 2.9 | Not reported | Not reported | Not reported |
|---|
12-months off therapy
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 0 |
|---|
| High-Risk Group | 0 |
|---|
24-months off therapy
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 6 |
|---|
| High-Risk Group | 0 |
|---|
Values in ng/mL · Interval/dispersion: Standard Deviation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Intermediate-Risk Group | 9.2 | 6.5 | Not reported | Not reported | Not reported |
|---|
36-months off therapy
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 0 |
|---|
| High-Risk Group | 0 |
|---|
48-months off therapy
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 0 |
|---|
| High-Risk Group | 0 |
|---|
60-months off therapy
Analysis denominator · Participants
| Group | Source count |
|---|
| Low-Risk Group | 0 |
|---|
| Intermediate-Risk Group | 0 |
|---|
| High-Risk Group | 0 |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG001
- spread
- 9.7
- value
- 15.3
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- End of induction
- categories
- measurements
- group Id
- OG001
- spread
- 6.2
- value
- 13.4
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 8
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- End of therapy
- categories
- measurements
- group Id
- OG001
- spread
- 2.9
- value
- 7.3
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- 6-months off therapy
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- 12-months off therapy
- categories
- measurements
- group Id
- OG001
- spread
- 6.5
- value
- 9.2
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 6
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- 24-months off therapy
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- 36-months off therapy
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- 48-months off therapy
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- units
- Participants
- title
- 60-months off therapy
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 20
- group Id
- OG002
- value
- 0
- units
- Participants
- description
- Growth hormone secretion was measured in consenting intermediate risk patients at the end of induction therapy, the end of all therapy, and at 6, 12, 24, 36, 48, and 60 months off therapy. Mean growth hormone secretion values are reported by assessment time point. Please note the small numbers of participants with available data.
- dispersion Type
- Standard Deviation
- groups
- description
- Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
- id
- OG000
- title
- Low-Risk Group
- description
- Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
- id
- OG001
- title
- Intermediate-Risk Group
- description
- Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.
- id
- OG002
- title
- High-Risk Group
- param Type
- MEAN
- population Description
- Growth hormone secretion was measured in consenting intermediate risk patients. No Intermediate Risk patients had data available at 12, 36, 48, and 60 months off therapy.
- reporting Status
- POSTED
- time Frame
- End of induction therapy (approximately 16 weeks from start of treatment), end of therapy (approximately 48 weeks from start of treatment), and 6, 12, 24, 36, 48, and 60 months off therapy
- title
- Growth Hormone Secretion
- type
- SECONDARY
- unit Of Measure
- ng/mL
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle